• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

伊斯法罕市卵巢癌患者与健康人群血清癌抗原125和人附睾蛋白4水平的比较。

Comparison of the Serum Level of Cancer Antigen 125 and Human Epididymis Protein 4 in Ovarian Cancer Patients and Healthy Groups in Isfahan City.

作者信息

Bakrani Mahnaz, Poor Kahin Shahani, Mehrzad Valiollah, Razmi Nematallah

机构信息

Department of Biochemistry, Shiraz Sciences and Research Branch, Islamic Azad University, Shiraz, Isfahan, Iran.

Department of Biochemistry, Falavarjan Branch, Islamic Azad University, Isfahan, Iran.

出版信息

Adv Biomed Res. 2017 Oct 16;6:124. doi: 10.4103/2277-9175.216778. eCollection 2017.

DOI:10.4103/2277-9175.216778
PMID:29142887
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5672644/
Abstract

BACKGROUND

Ovarian cancer is the most common fatal malignancy of the gynecology tract. The purpose of this study was to compare serum levels of tumor markers cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) in both healthy groups and patients with ovarian cancer.

MATERIALS AND METHODS

this case-control study was performed on Seyed Al-Shohada Hospital in Isfahan. Research on the treatment of 44 patients with ovarian cancer and 44 healthy controls was performed. CA125 and HE4 were measured in serum by sandwich ELISA method.

RESULTS

Average CA125 in ovarian cancer patients (83.30 ± 43.99 μ/ml) was significantly higher than in healthy controls (12.39 ± 5.50 μ/ml) ( < 0.001). Average HE4 in ovarian cancer patients (295.41 ± 133.33 PM) was significantly higher than in healthy controls (114.64 ± 17.31 PM) ( < 0.001).

CONCLUSIONS

HE4 test is complementary of CA125 test in women with epithelial ovarian cancer. It is also used to study the disease process.

摘要

背景

卵巢癌是妇科最常见的致命恶性肿瘤。本研究的目的是比较健康组和卵巢癌患者血清中肿瘤标志物癌抗原125（CA125）和人附睾蛋白4（HE4）的水平。

材料与方法

本病例对照研究在伊斯法罕的赛义德·阿尔-肖哈达医院进行。对44例卵巢癌患者和44例健康对照者进行了研究。采用夹心酶联免疫吸附测定法检测血清中的CA125和HE4。

结果

卵巢癌患者的CA125平均水平（83.30±43.99μ/ml）显著高于健康对照者（12.39±5.50μ/ml）（<0.001）。卵巢癌患者的HE4平均水平（295.41±133.33皮摩尔）显著高于健康对照者（114.64±17.31皮摩尔）（<0.001）。

结论

HE4检测是上皮性卵巢癌患者CA125检测的补充。它也用于研究疾病进程。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e694/5672644/f7d820168850/ABR-6-124-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e694/5672644/afce50f208cc/ABR-6-124-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e694/5672644/e6af7ef0e34d/ABR-6-124-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e694/5672644/e64816141bcc/ABR-6-124-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e694/5672644/f7d820168850/ABR-6-124-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e694/5672644/afce50f208cc/ABR-6-124-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e694/5672644/e6af7ef0e34d/ABR-6-124-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e694/5672644/e64816141bcc/ABR-6-124-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e694/5672644/f7d820168850/ABR-6-124-g004.jpg

相似文献

1
Comparison of the Serum Level of Cancer Antigen 125 and Human Epididymis Protein 4 in Ovarian Cancer Patients and Healthy Groups in Isfahan City.伊斯法罕市卵巢癌患者与健康人群血清癌抗原125和人附睾蛋白4水平的比较。
Adv Biomed Res. 2017 Oct 16;6:124. doi: 10.4103/2277-9175.216778. eCollection 2017.
2
[Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].血清癌抗原125、人附睾蛋白4、ROMA及CPH-I在中国卵巢肿物患者中诊断卵巢癌的比较
Nan Fang Yi Ke Da Xue Xue Bao. 2019 Dec 30;39(12):1393-1401. doi: 10.12122/j.issn.1673-4254.2019.12.02.
3
Correlation of Molecular Tumor Markers CA125, HE4, and CEA with the Development and Progression of Epithelial Ovarian Cancer.分子肿瘤标志物CA125、HE4和CEA与上皮性卵巢癌发生发展的相关性
Iran J Public Health. 2021 Jun;50(6):1197-1205. doi: 10.18502/ijph.v50i6.6418.
4
Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.上皮性卵巢癌患者卵巢恶性肿瘤风险的诊断措施比较：一项荟萃分析。
Sci Rep. 2021 Aug 27;11(1):17308. doi: 10.1038/s41598-021-96552-9.
5
Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.HE4 评估与 CA125 比较在卵巢癌诊断和治疗反应评估中的意义。
Diagn Pathol. 2013 Jan 23;8:11. doi: 10.1186/1746-1596-8-11.
6
HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.人附睾蛋白4、癌抗原125、恶性风险算法和恶性风险指数与复杂盆腔肿块——澳大利亚人群盆腔肿块术前评估中的前瞻性比较
Aust N Z J Obstet Gynaecol. 2015 Oct;55(5):493-7. doi: 10.1111/ajo.12363. Epub 2015 Jul 14.
7
Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.评估人附睾蛋白4（HE4）和卵巢恶性肿瘤风险算法（ROMA）作为日本女性I型和II型上皮性卵巢癌诊断工具的价值。
Tumour Biol. 2015 Feb;36(2):1045-53. doi: 10.1007/s13277-014-2738-7. Epub 2014 Oct 19.
8
Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.组织CA125和HE4基因表达水平在鉴别盆腔良恶性肿块方面具有更高的准确性。
Asian Pac J Cancer Prev. 2016;17(1):323-33. doi: 10.7314/apjcp.2016.17.1.323.
9
Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.血清 CA125、HE4 和 TK1 联合检测在卵巢癌诊断中的应用价值研究。
Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4536-4541.
10
[Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].人附睾蛋白4与CA125联合检测在卵巢恶性肿瘤患者中的诊断价值
Zhonghua Zhong Liu Za Zhi. 2011 Jul;33(7):540-3.

本文引用的文献

1
The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass.HE4 在亚洲盆腔肿块女性卵巢癌预测中的应用。
Gynecol Oncol. 2013 Feb;128(2):239-44. doi: 10.1016/j.ygyno.2012.09.034. Epub 2012 Oct 10.
2
Human epididymis protein 4 (HE4) and ovarian cancer prognosis.人附睾蛋白 4（HE4）与卵巢癌预后。
Gynecol Oncol. 2012 Dec;127(3):511-5. doi: 10.1016/j.ygyno.2012.09.003. Epub 2012 Sep 9.
3
Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.卵巢癌的筛查、诊断和监测生物标志物。
Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):1902-12. doi: 10.1158/1055-9965.EPI-12-0646. Epub 2012 Sep 7.
4
HE4 is an independent prognostic marker in endometrial cancer patients.HE4 是子宫内膜癌患者的独立预后标志物。
Gynecol Oncol. 2012 Aug;126(2):186-91. doi: 10.1016/j.ygyno.2012.04.022. Epub 2012 Apr 21.
5
Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.血清中卵巢癌标志物 HE4 的水平在妊娠期间降低，并随年龄增长而升高。
Am J Obstet Gynecol. 2012 Apr;206(4):349.e1-7. doi: 10.1016/j.ajog.2011.12.028. Epub 2011 Dec 30.
6
HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm.HE4 和上皮性卵巢癌：两种免疫分析法和联合算法的比较和临床评估。
Clin Chim Acta. 2011 Jul 15;412(15-16):1447-53. doi: 10.1016/j.cca.2011.04.028. Epub 2011 Apr 30.
7
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.使用症状指数、CA125和HE4预测卵巢癌。
Gynecol Oncol. 2010 Mar;116(3):378-83. doi: 10.1016/j.ygyno.2009.10.087. Epub 2009 Nov 28.
8
HE4 as a biomarker for ovarian and endometrial cancer management.人附睾蛋白4作为卵巢癌和子宫内膜癌管理的生物标志物。
Expert Rev Mol Diagn. 2009 Sep;9(6):555-66. doi: 10.1586/erm.09.39.
9
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.使用多种新型肿瘤生物标志物检测盆腔肿块患者的卵巢癌。
Gynecol Oncol. 2008 Feb;108(2):402-8. doi: 10.1016/j.ygyno.2007.10.017. Epub 2007 Dec 3.
10
Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range.血清CA-125水平在正常范围内升高的上皮性卵巢癌患者的复发风险。
J Clin Oncol. 2005 Dec 20;23(36):9338-43. doi: 10.1200/JCO.2005.02.2582.